BMS, Lilly Reach Agreement To Co-Develop Erbitux Follow-On
This article was originally published in The Pink Sheet Daily
Executive Summary
During its fourth-quarter 2009 earnings call, Bristol also urged investors to show patience with disappointing sales of Onglyza.
You may also be interested in...
Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta
With Super Bowl mania rampant, what are the chances of the biopharmaceutical industry’s equivalent: a mega-merger within big pharma? A Wall Street analyst downplays the likelihood of another Pfizer/Wyeth-like pairing, but raises the possibility that industry will see a mid-sized deal intended to mimic the success of the Sanofi/Genzyme merger.
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.